Nautilus Biotechnology, Inc. (NAUT) Bundle
Understanding Nautilus Biotechnology, Inc. (NAUT) Revenue Streams
Understanding Nautilus Biotechnology, Inc.’s Revenue Streams
As of September 30, 2024, Nautilus Biotechnology, Inc. has not yet generated any revenue from product sales since its inception. The company continues to invest heavily in research and development to commercialize its proteomics platform.
Revenue Breakdown
The company’s revenue streams are currently non-existent as it is still in the development phase. Historical financial data shows:
- Net Loss (Q3 2024): $16.4 million
- Net Loss (Q3 2023): $15.9 million
- Net Loss (9 months ended September 30, 2024): $53.2 million
- Net Loss (9 months ended September 30, 2023): $46.7 million
As of September 30, 2024, the company had an accumulated deficit of $255.4 million.
Year-over-Year Revenue Growth Rate
Since there are no recorded sales, the year-over-year revenue growth rate remains at 0%. The focus remains on increasing the capabilities of its proteomics platform, which has led to increased operating losses instead of revenue growth.
Contribution of Different Business Segments
All financial activity is currently concentrated in research and development and general administrative expenses, with operating expenses for:
| Category | Q3 2024 (in thousands) | Q3 2023 (in thousands) | 9 Months 2024 (in thousands) | 9 Months 2023 (in thousands) |
|---|---|---|---|---|
| Research and Development | 12,288 | 11,996 | 37,654 | 34,785 |
| General and Administrative | 6,812 | 7,079 | 23,842 | 21,366 |
| Total Operating Expenses | 19,100 | 19,075 | 61,496 | 56,151 |
Significant Changes in Revenue Streams
As of September 30, 2024, there have been no significant changes in revenue streams, as the company continues to operate without generating sales. The focus remains on the development of its proteomics platform, with the expectation of future commercialization efforts.
Overall, the financial health of Nautilus Biotechnology, Inc. is characterized by substantial investments in development and a lack of revenue generation, which poses challenges for its operational sustainability moving forward.
A Deep Dive into Nautilus Biotechnology, Inc. (NAUT) Profitability
A Deep Dive into Nautilus Biotechnology, Inc.'s Profitability
Gross Profit Margin: As of September 30, 2024, the company reported a net loss of $16.4 million for the third quarter and $53.2 million for the nine months ended September 30, 2024. The gross profit margin is not applicable as the company has not generated any revenue from product sales since its inception.
Operating Profit Margin: Total operating expenses for the nine months ended September 30, 2024, were $61.5 million, compared to $56.2 million during the same period in 2023. This reflects an increase in operating expenses due to higher research and development costs, which totaled $37.7 million for the nine months ended September 30, 2024.
Net Profit Margin: The net loss per share attributable to common stockholders for the nine months ended September 30, 2024, was $(0.42), compared to $(0.37) for the nine months ended September 30, 2023.
Trends in Profitability Over Time
The company has consistently reported net losses since its inception. The net loss for the nine months ended September 30, 2024, was $53.2 million, reflecting an increase from $46.7 million for the same period in 2023. The continuous investment in research and development and general administrative expenses have contributed to these losses.
Comparison of Profitability Ratios with Industry Averages
Given that the company is in a development stage and has not yet generated revenue, direct comparisons to industry averages for gross, operating, and net profit margins are not applicable. However, the biotechnology industry typically sees similar trends in early-stage companies, where substantial investments in R&D lead to operating losses until products are brought to market.
Analysis of Operational Efficiency
The total operating expenses increased by 8.2% from $56.2 million in the first nine months of 2023 to $61.5 million in 2024. This increase was driven primarily by:
- Research and Development Expenses: $37.7 million
- General and Administrative Expenses: $23.8 million
In terms of operational efficiency, the company continues to manage costs but has not yet achieved profitability. The gross margin remains negative due to the absence of product sales, which is typical for companies in this phase.
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Loss | $16.4 million | $15.9 million | $53.2 million | $46.7 million |
| Operating Expenses | $19.1 million | $19.1 million | $61.5 million | $56.2 million |
| Research and Development Expenses | $12.3 million | $12.0 million | $37.7 million | $34.8 million |
| General and Administrative Expenses | $6.8 million | $7.1 million | $23.8 million | $21.4 million |
The analysis indicates that while the company is maintaining a level of cost management, the ongoing net losses signal the challenges it faces in achieving operational efficiency and profitability.
Debt vs. Equity: How Nautilus Biotechnology, Inc. (NAUT) Finances Its Growth
Debt vs. Equity: How Nautilus Biotechnology, Inc. Finances Its Growth
Debt Levels:
As of September 30, 2024, the company had total liabilities amounting to $36.3 million, which includes current liabilities of $8.7 million and long-term lease liabilities of $27.6 million.
Debt-to-Equity Ratio:
The debt-to-equity ratio stands at approximately 0.16, calculated by dividing total liabilities by total stockholders' equity of $223.4 million.
Recent Debt Issuances and Credit Ratings:
Recent financing activities included a sales agreement in February 2024 with Cowen and Company for an "at the market" offering program allowing the sale of up to $125 million in common stock. The company has not issued significant new debt recently, focusing instead on equity financing.
Equity Funding:
Since the business combination in June 2021, the company raised approximately $345.5 million through PIPE financing, offset by transaction costs of $18.2 million. As of September 30, 2024, total stockholders' equity reached $223.4 million.
Balance Between Debt Financing and Equity Funding:
The company has primarily relied on equity funding to support its operations, as evidenced by its accumulated deficit of $255.4 million as of September 30, 2024, indicating significant prior losses. The balance between debt and equity financing reflects a conservative approach, maintaining low levels of debt relative to equity, allowing for flexibility in funding future growth.
| Financial Metric | Amount |
|---|---|
| Total Liabilities | $36.3 million |
| Current Liabilities | $8.7 million |
| Long-term Lease Liabilities | $27.6 million |
| Debt-to-Equity Ratio | 0.16 |
| Total Stockholders' Equity | $223.4 million |
| Accumulated Deficit | $255.4 million |
| Total Equity Raised (PIPE Financing) | $345.5 million |
| Transaction Costs from PIPE Financing | $18.2 million |
| Sales Agreement Amount | $125 million |
Assessing Nautilus Biotechnology, Inc. (NAUT) Liquidity
Assessing Nautilus Biotechnology, Inc.'s Liquidity
Current and Quick Ratios
The liquidity position of Nautilus Biotechnology, Inc. can be assessed through its current and quick ratios. As of September 30, 2024, the company reported:
- Current Assets: $140.6 million
- Current Liabilities: $17.2 million
- Current Ratio: 8.16
- Quick Assets: $140.6 million (assuming no inventory)
- Quick Ratio: 8.16
Analysis of Working Capital Trends
Working capital, defined as current assets minus current liabilities, provides insight into the short-term financial health of the company. As of September 30, 2024:
- Working Capital: $123.4 million
This indicates a strong liquidity position, allowing the company to cover its short-term obligations comfortably.
Cash Flow Statements Overview
The cash flow statements for the nine months ended September 30, 2024, compared to the same period in 2023, reveal the following trends:
| Cash Flow Activity | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net cash used in operating activities | ($44,836) | ($37,811) |
| Net cash provided by investing activities | $29,144 | ($2,675) |
| Net cash provided by financing activities | $704 | $115 |
| Net increase (decrease) in cash | ($14,988) | ($40,371) |
Potential Liquidity Concerns or Strengths
Despite the strong current and quick ratios, the company has faced significant net losses and cash outflows:
- Net Loss (2024): $53.2 million
- Accumulated Deficit: $255.4 million as of September 30, 2024
- Cash, cash equivalents, and investments: $140.6 million
This indicates that while Nautilus has a robust liquidity position, continued net losses and reliance on external financing for operations could pose future liquidity risks.
Is Nautilus Biotechnology, Inc. (NAUT) Overvalued or Undervalued?
Valuation Analysis
To determine whether Nautilus Biotechnology, Inc. is overvalued or undervalued, we will examine key financial metrics such as price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA) ratios, along with stock price trends and analyst consensus.
Price-to-Earnings (P/E) Ratio
As of September 30, 2024, the company's net loss was $53.2 million, resulting in a net loss per share of $0.42 for the nine months ended September 30, 2024. Given that the company has not generated revenue, the P/E ratio is not applicable.
Price-to-Book (P/B) Ratio
The total stockholders’ equity as of September 30, 2024, was $223.4 million. The number of shares outstanding was 125,560,309, leading to a book value per share of approximately $1.78. If the current stock price is $2.50, the P/B ratio would be approximately 1.4.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
As of September 30, 2024, Nautilus had cash, cash equivalents, and short-term investments totaling $140.6 million. The enterprise value (EV) can be calculated as:
- Market Capitalization: 125,560,309 shares x $2.50 = $313.9 million
- Debt: $0 (no long-term debt reported)
- Cash: $140.6 million
- Enterprise Value = Market Cap - Cash = $313.9 million - $140.6 million = $173.3 million
For the nine months ended September 30, 2024, the total operating loss was $53.2 million, thus:
- EV/EBITDA = EV / EBITDA = $173.3 million / -$53.2 million
The EV/EBITDA ratio is negative due to the operating loss, indicating that traditional valuation metrics may not apply.
Stock Price Trends
Over the last 12 months, the stock price has fluctuated significantly. The stock opened at $3.00 and has seen a high of $4.50 and a low of $1.50, reflecting a current price of $2.50.
Dividend Yield and Payout Ratios
The company does not pay dividends, resulting in a dividend yield of 0%.
Analyst Consensus on Stock Valuation
Analysts currently have a consensus rating of Hold for the stock, with price targets ranging from $2.00 to $3.50.
| Metric | Value |
|---|---|
| P/E Ratio | N/A |
| P/B Ratio | 1.4 |
| EV/EBITDA | N/A |
| Net Loss (9M 2024) | $53.2 million |
| Book Value per Share | $1.78 |
| Current Stock Price | $2.50 |
| Analyst Consensus | Hold |
Key Risks Facing Nautilus Biotechnology, Inc. (NAUT)
Key Risks Facing Nautilus Biotechnology, Inc.
The company faces several internal and external risks that impact its financial health, primarily due to its status as a development-stage entity.
Industry Competition
The biotechnology sector is highly competitive, with numerous firms developing similar technologies. The success of the company's platform depends on its ability to differentiate itself from competitors.
Regulatory Changes
Regulatory compliance is essential for market entry. The company’s products may be subject to regulation by the FDA or other authorities, which could introduce delays or costs that impact financial performance.
Market Conditions
Fluctuations in market conditions can affect funding and investment opportunities. Economic downturns may limit access to capital, which is critical for ongoing development efforts.
Operational Risks
- Dependence on Key Personnel: The company relies heavily on its management and technical teams. Loss of key personnel could hinder progress.
- Supply Chain Disruptions: Global supply chain interruptions may negatively impact product development and commercialization efforts.
Financial Risks
The company has incurred significant losses, reporting a net loss of $53.2 million for the nine months ended September 30, 2024, compared to a net loss of $46.7 million in the same period of 2023.
Strategic Risks
The company is in a critical phase of developing its Nautilus platform. If it fails to commercialize this technology successfully, it may never generate sufficient revenue to sustain operations.
Mitigation Strategies
The company is actively working to build its marketing and sales infrastructure to support the commercialization of its products. Additionally, it has entered into a sales agreement to potentially raise $125 million through an “at the market” offering program.
| Risk Type | Description | Recent Financial Impact |
|---|---|---|
| Operational | Dependence on key personnel and supply chain disruptions | Net loss of $53.2 million for the nine months ended September 30, 2024 |
| Financial | Significant operating losses | Accumulated deficit of $255.4 million as of September 30, 2024 |
| Regulatory | Compliance with FDA and other regulations | Potential delays in product launch |
| Market | Fluctuating market conditions affecting funding | Challenges in raising additional capital |
The company’s ability to navigate these risks will be crucial for its financial health and long-term sustainability. As of September 30, 2024, the company had cash, cash equivalents, and short-term investments totaling $140.6 million, which it believes will support operations for at least the next 12 months.
Future Growth Prospects for Nautilus Biotechnology, Inc. (NAUT)
Future Growth Prospects for Nautilus Biotechnology, Inc.
Analysis of Key Growth Drivers
The company is positioning itself for future growth through several key drivers:
- Product Innovations: The Nautilus platform aims to revolutionize protein analysis with its end-to-end solution comprising instruments, consumables, and software analysis.
- Market Expansions: The company is exploring new markets for its products, potentially increasing its customer base and revenue streams.
- Acquisitions: Strategic acquisitions may be pursued to enhance technological capabilities and expand market reach.
Future Revenue Growth Projections and Earnings Estimates
Projected revenue growth is contingent on the successful commercialization of the Nautilus platform. Analysts estimate that revenues could reach approximately $100 million by 2026, assuming successful product launches and market penetration.
Current earnings estimates predict that the company will continue to experience losses in the near term, with a net loss of $53.2 million reported for the nine months ended September 30, 2024.
Strategic Initiatives or Partnerships
In February 2024, the company entered into a sales agreement with Cowen and Company, allowing it to offer and sell up to $125 million of its common stock through an at-the-market offering. This capital will support ongoing research and development efforts.
Additionally, the company is actively seeking partnerships with academic institutions and industry leaders to enhance its research capabilities and accelerate product development.
Competitive Advantages
The company possesses several competitive advantages that position it favorably for growth:
- Innovative Technology: The Nautilus platform utilizes proprietary technology that provides unique insights into protein analysis, setting it apart from competitors.
- Strong Intellectual Property Portfolio: The company has invested significantly in securing patents and intellectual property, which can protect its innovations and provide a competitive edge.
- Experienced Management Team: The leadership team has extensive experience in biotechnology and commercialization, which enhances the company's strategic direction.
Financial Overview
As of September 30, 2024, the company reported a cash balance of $4.4 million and short-term investments of $136.2 million, providing a solid foundation for future growth initiatives. The total stockholders' equity stood at $223.4 million.
Table: Financial Performance Summary
| Financial Metric | As of September 30, 2024 | As of September 30, 2023 |
|---|---|---|
| Net Loss | $53.2 million | $46.7 million |
| Cash and Cash Equivalents | $4.4 million | $19.4 million |
| Short-term Investments | $136.2 million | $154.0 million |
| Total Stockholders' Equity | $223.4 million | $265.4 million |
Nautilus Biotechnology, Inc. (NAUT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Nautilus Biotechnology, Inc. (NAUT) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Nautilus Biotechnology, Inc. (NAUT)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Nautilus Biotechnology, Inc. (NAUT)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.